Q BioMed's Strontium89 Advertisement "Unfinished Business" for inclusion in Ads of the World's Best Creative Campaigns

Q BioMed Inc. | November 21, 2020

Q BioMed Inc., announces that the advertising effort for Strontium89 (Strontium Chloride Sr-89 Injection, USP), the Company's FDA affirmed treatment that objectives agonizing bone metastases, has been chosen for consideration in Ads of the World, a cautiously curated chronicle of the world's best innovative missions. The choice models for consideration directs that lone the most elevated type of innovative work gets distributed.

Strontium89, the radiotherapy with almost 30 years of demonstrated outcomes in soothing excruciating bone metastases, is accessible in the US from Q BioMed. In the Strontium89 urgent preliminary, the same number of as 79% of patients had relief from discomfort with Strontium89, and twice the same number of patients treated with Strontium89 had no agony for a very long time contrasted and fake treatment. Further, new agony locales were less successive in patients treated with Strontium891,2.

Spotlight

Since Playwire’s inception 15+ years ago, our data collection and targeting capabilities have been at the core of our ability to deliver high-performing, revenue-amplifying ad tech strategies for both publishers and advertisers.

Now, using all we have learned over the years, we are proud to offer direct access to our exclusive data and custom segmentation as a standalone solution for audience targeting.


Other News

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Spotlight

Since Playwire’s inception 15+ years ago, our data collection and targeting capabilities have been at the core of our ability to deliver high-performing, revenue-amplifying ad tech strategies for both publishers and advertisers.

Now, using all we have learned over the years, we are proud to offer direct access to our exclusive data and custom segmentation as a standalone solution for audience targeting.

Resources